Articles On Pharmaxis (ASX:PXS)

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Summary Digital health behemoth ResMed has released its quarterly results for the March 2021 quarter reporting flat sales. The Company witnessed lower device sales and decreased demand for its ventilators due to COVID-19. However, str...

Inflammatory diseases company Pharmaxis (ASX:PSX) this month welcomed a familiar biotech name to the register: Karst Peak Capital. The Hong Kong and Sydney based ‘contrarian’ fund manager is also a major holder in Neuren and Cyclopharm, and...

The clinical stage drug development company has boosted its balance sheet with a $4.4 million placement and the sale of Bronchitol Russian distribution rights for $2 million.

If you want to know which ASX stocks fund managers and famous investors are putting their money into we’ve been keeping track of substantial holder buys (and sells). Trading Places is Stockhead’s recap of the substantial holder movements am...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With stock...

Australian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy BRONCHITOL (mannitol) and completed a $4.4 million placement to institutional investors.

Source: Monster Ztudio, Shutterstock Summary Pharmaxis’ shares rose on the sale of Russian distribution rights for Bronchitol ®. The pharmaceutical research firm will get A$2 million distributor appointment fee. The drug maker is rai...

After a few near misses, the ASX has punched through 7,000 percentage points for the first time since the COVID-19 market crash. The ASX 200 rose by 0.70 per cent to 7,025 points while the ASX Emerging Companies Index rose by 0.56 per cent...

The company has also strengthened its balance sheet with the sale of Bronchitol Russian distribution rights for A$2 million with annual A$1 million cost savings.

Source: Jirapong Manustrong, Shutterstock The ASX 200 is trading in the positive territory today. The benchmark lost some points in the first 15 minutes post market open. However, post the initial blip the market has steadily moved up. By...

ShareCafeAustralia…1 hour in… ASX200 up 18 ASX200 up 18 points (0.3%) to 6994   Brainchip (+18%); begins production of Akida AI Processor. Capral (+16%); has received a confidential nonbinding indicative proposal from Allegro Funds to acqu...

Today, the ASX finished slightly in the green, tech stocks were up over 2 per cent, and another IPO gained over 100 per cent. The ASX 200 rose 0.04 per cent, closing at 6,977 points. Meanwhile, the ASX Emerging Companies Index rose 0.36 per...

ShareCafeAustralia…1 hour in… ASX200 up 15 ASX200 up 15 points (0.2%) to 6989   A2Milk (+3%); upgraded by 2 brokers this morning. ANZ (-0.1%); ratings agency Fitch has upgraded its outlook on ANZ from negative to stable. Bingo (+8.2%); on...

Pharmaxis (ASX:PSX) has announced a partnership to launch a world-first clinical trial that aims to stop scars from forming after trauma, particularly following burn injuries.

Risk on sentiment has returned to the ASX. The ASX finished 0.78 per cent higher at 6,791 points although it peaked at 6,861 earlier today, which was nearly 2 per cent higher than the day before. The ASX Emerging Companies Index however los...

The trial will investigate the potential of PXS‐6302 treatment to transform trauma recovery by blocking the underlying fibrosis causing scar tissue.

Pharmaxis (ASX:PXS) has announced that its US partner Chiesi has launched BRONCHITOL (mannitol) in the US.

US stocks dip as Treasury yields spike US stocks dipped from record highs on Thursday trading in the US, as US treasury yields spiked. The 10-year benchmark yield surged to 1.73%, rising from 1.68% yesterday. Despite the signal the Fed is s...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Australian pharmaceutical company Pharmaxis (ASX:PXS) has enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis.

Summary ASX-listed Pharmaxis has enrolled the first patient for the clinical trial to evaluate a potential new treatment for bone marrow cancer. The study also includes a dose-escalation phase to select an optimum dose of PXS-5505. PX...

“Its potential to modify the course of the disease by directly targeting bone marrow fibrosis will make PXS‐5505 an ideal monotherapy or adjunct to approved therapies in this indication,” says CEO.

Summary Australian pharmaceutical research player Pharmaxis has shipped the first batch of Bronchitol to the American city. Atlanta. The Company said its US distributor initiated a further US$3 Mn-milestone payment. Pharmaxis anticipa...

“This represents a proud and very rare achievement for a home‐grown pharmaceutical research company,” says CEO Gary Phillips.

Pharmaxis (ASX:PXS) has triggered a US$3 million milestone payment after exporting the first shipment of its locally developed and manufactured drug BRONCHITOL (mannitol) to the US.

Pharmaxis (ASX:PXS) has received a US$7 million milestone payment from its US licensee Chiesi following the recent FDA approval of BRONCHITOL (mannitol) for the treatment of cystic fibrosis.

Summary Pharmaxis Ltd (ASX:PXS) has received a US$7 million milestone payment from Chiesi. The payment has been received post the FDA approval of Bronchitol® for treating cystic fibrosis. Pharmaxis  believes that the approval triggers...

Pharmaxis is now advancing clinical development of a new cancer drug.

The Pharmaxis Ltd (ASX: PXS) share price is up today on the news it has received a substantial payment from a strategic partner. The Pharmaxis share price reached an intraday high of 9.9 cents in late morning trade, but has since pulled ba...

Summary Leading medical imaging company Pro Medicus Limited has signed a five-year deal with MedStar Health. With this contract, the Company’s Visage 7 platform would be deployed entirely to the public cloud. The Company plans for the...

It is indeed possible to get something from nothing. Four small-caps appear to be defying the norms of capitalism. By Tim Boreham These companies are trading at close to cash backing, but are the discounts justified? “Something for nothing”...

The company expects to announce receipt of milestone payments and the start of sales from its Bronchitol treatment in the near-term.

Presenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:PXS).

Pharmaxis has become one of the small number of local life science companies to secure FDA approval of an Australian, developed, discovered and manufactured product.

ShareCafeBhronchitol FDA Approval Transformative for Pharmaxis Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced the United States Food and Drug Administration (FDA) has approved Bronchitol® (mannitol) as add‐on maint...

Pharmaxis Ltd (ASX: PXS) today published a quarterly update in which the company reported three significant events. Consequently, the Pharmaxis share price has shot up 47.73% to 13 cents this morning. The pharmaceutical research company is...

ShareCafeAustralia…One Hour In…ASX Up 6 Points ASX200 up 6 points (0.1%) to 5933. – AMP (+8.6%); says the Ares takeover proposal implies a value of $1.85 a share. Trading @ $1.65.– IAG (-0.8%); CEO Mark Milliner to leave. Nick Hawkins new C...

Australian drug discovery will now be available for cystic fibrosis patients in the USA in a “transformational” event for the company with cash flow generated to take lead pipeline drug to end of phase 2 clinical trials.

In what has been described as a “transformational step” Pharmaxis (ASX: PXS) has collared United States Food and Drug Administration approval for its Bronchitol drug (mannitol) to be used in the country as an adjunct therapy for cystic fibr...

The company is focused on the phase 1/2 clinical trial of its pan-LOX inhibitor PXS-505 in myelofibrosis and will use the tax incentive to progress the drug’s development.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes for the week It’s been...

A quick wrap of the ASX’s key winners and losers on Monday, September 7. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made market-moving announcements during the day. Today 847 stocks rose, 575 declined an...

Pharmaxis (ASX:PXS) and Biotron (ASX:BIT) have gone in polar opposite directions in 2020 and today the gap widened further. Biotron has now nearly doubled in 2020 while Pharmaxis has nearly halved. Pharmaxis ended 2019 with a big blow which...

ShareCafeAustralia…1 Hour In…ASX Up 12 Points ASX200 up 12 points (0.2%) to 5937. – Afterpay (-3.5%); still seeing selling as competition grows. Last week it was Pay Pal, today see’s another new Buy Now Pay Later listing – Laybuy Group (LBY...